Research programme: asthma/allergy therapy - Amgen

Drug Profile

Research programme: asthma/allergy therapy - Amgen

Alternative Names: Asthma/allergy research programme - Amgen

Latest Information Update: 14 Aug 2001

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Amgen
  • Class
  • Mechanism of Action Protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Asthma; Hypersensitivity

Most Recent Events

  • 14 Aug 2001 No-Development-Reported for Allergy in USA (PO)
  • 14 Aug 2001 No-Development-Reported for Asthma in USA (PO)
  • 07 Feb 2001 Kinetix Pharmaceuticals has been acquired by Amgen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top